Heterocyclic kinase inhibitors
This invention relates to novel 2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide derivatives, and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by the inhibition of kinases including Src-kinase and Bcr-Abl kinase.
1. A compound of Formula I:
or a salt thereof; wherein:
each W is independently selected from hydrogen or deuterium;
each Y is independently selected from hydrogen or deuterium;
each Z is independently selected from hydrogen or deuterium; and at least one W, Y, or Z is deuterium, wherein the compound is selected from the group consisting of the compounds defined in the table below:
Each
Each
Cmpd
Y 1
Each Y 2
Each Z
W 1
Each W 2
101
D
H
D
H
H
103
D
D
D
H
H
115
D
D
D
D
D
wherein any atom not designated as deuterium is present at its natural isotopic abundance.
2. A pyrogen-free pharmaceutical composition comprising a compound of claim 1 and an acceptable carrier.
3. A method of treating leukemia in a subject in need thereof, comprising administering to the subject a composition of claim 2 .
4. The method of claim 3 , wherein the leukemia is chronic myeloid leukemia or acute lymphoblastic leukemia.